Table 1.
Characteristics of all patients in the control and ruxolitinib group (N = 57).
| Control (n = 16) | Ruxolitinib (n = 41) | χ2 | P value | |
|---|---|---|---|---|
| Sex (n, %) | 0.299 | 0.585 | ||
| Male | 11 (68.8) | 25 (61.0) | ||
| Female | 5 (31.2) | 16 (39.0) | ||
| Primary disease (n, %) | 0.765 | 0.382 | ||
| ALL | 5 (31.2) | 18 (43.9) | ||
| AML | 11 (68.8) | 23 (56.1) | ||
| Gene mutation or fusion gene (n, %) | 1.435 | 0.231 | ||
| Yes | 10 (62.5) | 32 (78.0) | ||
| No | 6 (37.5) | 9 (22.0) | ||
| Abnormal chromosome (n, %) | 1.341 | 0.247 | ||
| Yes | 4 (25.0) | 17 (41.5) | ||
| No | 12 (75.0) | 24 (58.5) | ||
| Disease status at HSCT (n, %) | 1.93 | 0.381 | ||
| CR1 | 10 (62.5) | 32 (78.0) | ||
| CR2 and CR3 | 3 (18.75) | 3 (7.3) | ||
| NR | 3 (18.75) | 6 (14.7) | ||
| MRD (n, %) | 0.174 | 0.677 | ||
| Positive | 6 (37.5) | 13 (31.7) | ||
| Negative | 10 (62.5) | 28 (68.3) | ||
| Sex of donor–recipient (n, %) | 0.208 | 0.648 | ||
| Identical | 13 (81.3) | 31 (75.6) | ||
| Different | 3 (18.7) | 10 (24.4) | ||
| Donor–recipient ABO compatibility (n, %) | 2.557 | 0.110 | ||
| Compatible | 10 (62.5) | 16 (39.0) | ||
| Incompatible | 6 (37.5) | 25 (61.0) | ||
| Conditioning regimen (n, %) | 0.043 | 0.835 | ||
| TBI/Cy-based | 11 (68.7) | 27 (65.9) | ||
| Bu/Cy-based | 5 (31.3) | 14 (34.1) | ||
| Donor source (n, %) | 2.808 | 0.246 | ||
| Haploid donors | 10 (62.5) | 16 (39.0) | ||
| Matched unrelated donors | 5 (31.3) | 18 (43.9) | ||
| Mismatched unrelated donors | 1 (6.2) | 7(17.1) | ||
| Major gene mutation and/or fusion gene (n, %) | NA | NA | ||
| FLT3/ITD | 0 (0) | 9 (22.0) | ||
| TET2 | 6 (37.5) | 3(7.3) | ||
| BCR/ABL | 2 (12.5) | 5 (12.2) | ||
| CEBPA | 4 (25.0) | 5 (12.2) | ||
| Age | 14 (2–40) | 28 (1–56) | NA | NA |
| Age of donors | 37 (15–46) | 31 (12–60) | NA | NA |
| MNC × 108/kg | 10.6 (3.37–25.88) | 14.4 (3.11–32.8) | NA | NA |
| CD34 + × 108/kg | 6.45 (2.07–19.57) | 8.02 (2.13–18.69) | NA | NA |
| Time for engraftment of neutrophils (d) | 12 (10–28) | 13 (11–20) | NA | NA |
| Time for engraftment of PLT (d) | 13 (11–34) | 15 (12–34) | NA | NA |
ALL Acute lymphoblastic leukemia, AML acute myeloid leukemia, Bu busulfan, CR complete remission, Cy cyclophosphamide, HLA human leukocyte antigen, HSCT hematopoietic stem cell transplantation, MNC mononuclear cell, MRD minimal residual disease, NA not applicable, NR no remission, PLT platelet, TBI total-body irradiation.